Gene therapy data disappoints
BEAM is selling off violently after presenting updated clinical data for its alpha-1 antitrypsin deficiency treatment, with investors apparently unimpressed by the 18-month results despite some positive signals.
Sources: https://www.benzinga.com/pressreleases/26/09/g61652036/beam-therapeutics-presents-updated-clinical-data-phase-1-2-trial-beam-302-alpha-1-a
Previous verdicts for BEAM
- AI Search: Law Firm Investigation Adds Modest Overhang for BEAM — 2026-10-08
- ARK Buying Fuels BEAM Spike — 2026-09-22
- Safety jitters hit gene editing — 2026-09-10
- Gene therapy data whipsaws — 2026-09-09
- Gene therapy data whipsaws — 2026-09-08
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works